Bavarian nordic soars on multiple news items

Bavarian Nordic’s stock surged on the Copenhagen stock exchange Wednesday, increasing by 10 percent around 10:30 am. This rise is likely influenced by several pieces of news released after market close the previous day. Primarily, Bavarian Nordic announced a significant order from the European biomedical agency, Hera, for over 175,000 doses of its monkeypox vaccine Jynneos, meant for Africa amidst an outbreak. Alongside this, Bavarian Nordic donated 40,000 doses. As the sole approved provider of a monkeypox vaccine, outbreaks in Africa positively impact the company’s financials. The news of the African health authorities declaring the situation a ‘public health emergency’ has likely also affected the upwards stock trend. Lastly, the approval process for Bavarian Nordic’s vaccine candidate against the tropical disease chikungunya has been expedited in the US, with FDA expecting to decide on approval by February 12 at the latest.